These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17661658)

  • 1. New 'superbug' drug launched in the UK.
    Future Microbiol; 2006 Aug; 1(2):151-5. PubMed ID: 17661658
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections.
    Wilcox MH
    J Chemother; 2005 Aug; 17 Suppl 1():23-9. PubMed ID: 16285355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tigecycline: a new antibiotic.
    Hylands J
    Intensive Crit Care Nurs; 2008 Aug; 24(4):260-3. PubMed ID: 18554910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tigecycline pharmacokinetic/pharmacodynamic update.
    MacGowan AP
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i11-6. PubMed ID: 18684702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tigecycline: what is it, and where should it be used?
    Livermore DM
    J Antimicrob Chemother; 2005 Oct; 56(4):611-4. PubMed ID: 16120626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tigecycline, the first of a new class of antibiotics: the glycylcyclines].
    Bosó-Ribelles V; Roma-Sánchez E; Salavert-Lletí M; Hernández-Martí V; Poveda-Andrés JL
    Rev Esp Quimioter; 2007 Mar; 20(1):19-35. PubMed ID: 17530033
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tigecycline: antimicrobial action, chemotherapeutic efficacy and adverse reactions].
    Nikitin AV
    Antibiot Khimioter; 2009; 54(1-2):63-6. PubMed ID: 19499721
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
    Bradford PA; Weaver-Sands DT; Petersen PJ
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.
    Heizmann WR; Dupont H; Montravers P; Guirao X; Eckmann C; Bassetti M; García MS; Capparella MR; Simoneau D; Bodmann KF
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii45-55. PubMed ID: 23772046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tigecycline: 10 years of history and still in full force].
    Barberán J; Salso S; Alhambra A
    Rev Esp Quimioter; 2015 Apr; 28(2):61-78. PubMed ID: 25904513
    [No Abstract]   [Full Text] [Related]  

  • 11. Tigecycline: an antibiotic for the twenty-first century.
    Dryden M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii3-4. PubMed ID: 23772044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tigecycline: a review of a new glycylcycline antibiotic.
    Scheinfeld N
    J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline: an update.
    Stein GE; Babinchak T
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tigecycline use in patient with intra-abdominal abscess, beta-lactam allergy, and acute kidney injury.
    Ruiz-Tovar J; Beni R; Gras M
    Surg Infect (Larchmt); 2012 Oct; 13(5):340. PubMed ID: 23039235
    [No Abstract]   [Full Text] [Related]  

  • 15. Tigecycline: a new glycylcycline for treatment of serious infections.
    Noskin GA
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S303-14. PubMed ID: 16080069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emergence of clinical resistance to tigecycline.
    Sun Y; Cai Y; Liu X; Bai N; Liang B; Wang R
    Int J Antimicrob Agents; 2013 Feb; 41(2):110-6. PubMed ID: 23127485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An essential requirement for the licensing of new antibiotics is the provision of data on efficacy and safety obtained from clinical trials in which patients are randomized to receive either the experimental drug or a comparator antibiotic regarded as a standard treatment option. Preface.
    Johnson AP; Leibovici L
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii1. PubMed ID: 23930279
    [No Abstract]   [Full Text] [Related]  

  • 18. [Bacterial resistance and a new antibiotic: tigecycline].
    Gobernado M
    Rev Esp Quimioter; 2006 Sep; 19(3):209-19. PubMed ID: 17099789
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic challenges in the era of antibiotic resistance.
    Lee C
    Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S197-9. PubMed ID: 19134519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global monitoring of cross-resistance between tigecycline and minocycline, 2004-2009.
    Hawser SP
    J Infect; 2010 May; 60(5):401-2. PubMed ID: 20211200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.